About MIEBO

HOW MIEBO WORKS

MIEBO spreads quickly and evenly to form
a protective layer on the ocular surface, preventing tear evaporation1-5*

Droplet with logo mark 1

Mimics key functions of natural meibum and helps stabilize the tear film1-3,5,6*

Droplet with logo mark 2

Promotes healing on the ocular surface1,3*

Droplet with logo mark 3

May reduce friction7-9*

*The exact mechanism of action for MIEBO in DED is not known.1

  • Droplet with logo mark 1

    Mimics key functions of natural meibum and helps stabilize the tear film1-3,5,6*

  • Droplet with logo mark 2

    Promotes healing on the ocular surface1,3*

  • Droplet with logo mark 3

    May reduce friction7-9*

*The exact mechanism of action
for MIEBO in DED is not known.1

HOW MIEBO WORKS

WATCH VIDEO

UNIQUE FEATURES, GENTLE FORMULA1,7,8

MIEBO contains only ONE ingredient—not found in
any other Rx products for DED1

  • Vehicle free
  • Preservative free
  • Steroid free
  • Water free
icon clock
LONG LASTING

Resides in tears for up to 8 hours (PK rabbit study)10†

See more
Detection of MIEBO in Tears
Detection of MIEBO in Tears
MIEBO PK chart MIEBO PK chart

PFHO, perfluorohexyloctane; PK, pharmacokinetic.

†The ocular pharmacokinetics and biodistribution of PFHO were evaluated following single and multiple topical ocular administrations of radiolabeled 14C-PFHO in Dutch-Belted rabbits. A total of 45 rabbits received either a single dose (35 μL per eye) or multiple doses (twice daily for 5 days) of PFHO. Ocular tissues (ie, tears) were collected at multiple time points (up to 24 hours) for quantification of radioactivity using liquid scintillation counting and autoradiography. PFHO levels were measured in tears and ocular tissues. 14C-PFHO was detected in tears for up to 8 hours following a single dose administration. The clinical significance of this data has not been established.10

See less
icon water drop
QUICK AND EVEN SPREADING

Due to low surface tension, forming a protective layer1-5‡

‡See more

The above animations are illustrative of a single drop of MIEBO or saline applied from identical pipettes to a glass eye model.5

‡Formulations containing water may have a brief residence time of 3-5 minutes on the ocular surface and a high surface tension that hinders spreading.5,11

See less

SCIENCE OF MIEBO

Only MIEBO forms a protective layer, supporting ocular surface homeostasis1-3,12*

Due to its unique structure, perfluorohexyloctane has dual affinity for air and lipids, forming a
monolayer at the air-liquid interface of the tear film.1,3,4,9

Molecular composition of MIEBO vs tear film lipid layer Molecular composition of MIEBO vs tear film lipid layer

MIEBO is the ONLY Rx eye drop with preclinical data supporting evaporation inhibition3

In an in vitro study, MIEBO inhibited evaporation more effectively than natural human meibum3

Mean Evaporation Rates of Saline With Meibum Lipids and/or MIEBO§

Bar graph of mean evaporation rates of saline with meibum lipids and/or MIEBO*
  • there was no significant difference between the evaporation rate (Revap) of saline with only MIEBO layered on top compared with both meibum lipids and MIEBO layered on top (P>0.5).3

The clinical significance of this data has not been established.

Droplet with callout: MIEBO was 4x MORE EFFECTIVE at inhibiting evaporation vs meibum lipids[2]

Study design: The inhibitory effect of MIEBO vs meibum on the Revap of saline was evaluated in an in vitro model. Meibum lipids were collected from a single healthy volunteer. The Revap of saline was measured gravimetrically at 35 °C after layering either a single drop of MIEBO or the collected human meibum lipids to approximate the tear lipid layer in vivo over the top of 1 mL saline in a plastic container with a surface area approximating that of the human ocular surface. Evaporation rates are presented as standard error of the mean.3

§Percentage values are percent inhibition of the Revap of saline. Numbers in parentheses are the number of determinations. P values to test for significance were measured using the t test.3

The exact mechanism of action for MIEBO in DED is not known.1

In 2 in vitro studies, MIEBO inhibited evaporation more effectively than artificial tears3,13

Mean Evaporation Rates of Saline With Artificial Tears or MIEBO

Bar graph of mean evaporation rates of saline with artificial tears or MIEBO*
  • At 100 μL, MIEBO inhibited the evaporation rate of saline by 76%-81% (P<0.0001)3,13
  • The addition of various artificial tear eye drops at 100 μL had no influence on the Revap of saline (P≥0.12 vs saline alone)3,13

The clinical significance of this data has not been established.

Droplet with callout: MIEBO significantly INHIBITED THE EVAPORATION RATE of saline, unlike artificial tears[2]

Study design: The Revap of saline was measured following application of either MIEBO or different OTC artificial tears. The Revap was measured gravimetrically at 25 °C (Study 1) or at 35 °C (Study 2) using an analytical balance after layering 100 μL of MIEBO or artificial tears on the surface of 1 mL of saline in a container with a surface area similar to that of the human ocular surface. The evaporation rates are presented as mean (standard error of the mean). Results showed the Revap of saline was inhibited by 81% at 25 °C and by 76% at 35 °C when layering 100 μL MIEBO over saline while the evaluated artificial tears were without effect.3,13

Numbers in parentheses are the number of determinations. p values to test for significance vs saline alone were measured using the t test.3,13

All brand names and trademarks used herein are the property of their respective owners; Systane Ultra (Alcon, Fort Worth, Texas), Systane Balance (Alcon, Fort Worth, Texas), Soothe XP (Bausch + Lomb, Bridgewater, New Jersey), Systane Pro PF (Alcon, Fort Worth, Texas). No clinical efficacy is implied.

In an in vitro study, MIEBO inhibited evaporation more effectively than Vevye14

Evaporation Rates of Saline With 11 µL MIEBO or Vevye#

Bar graph of mean evaporation rates of saline with artificial tears or MIEBO*
  • A single drop of MIEBO significantly inhibited saline evaporation, while the same volume of Vevye did not14

The clinical significance of this data has not been established.

Droplet with callout: MIEBO significantly INHIBITED THE EVAPORATION RATE of saline, unlike artificial tears[2]

Study design: To evaluate the effect of MIEBO or Vevye on the Revap of saline, 1 mL of saline was added to a container with a surface area similar to that of the human ocular surface. The Revap of saline alone or saline with 11 μL of the MIEBO or Vevye layered over top were evaluated gravimetrically at 35 °C. Total sample weight was recorded every
10 min over 100 min, and Revap was obtained from the slope of the best-fit line obtained by least squares linear regression analysis. 11 µL is equivalent to 1 drop of MIEBO when dosed on the eye.14

#Numbers in parentheses are the number of determinations. P values to test significance vs saline alone were measured using the t test.14

All brand names and trademarks used herein are the property of their respective owners; Vevye (Harrow, Inc., Nashville, TN). No clinical efficacy is implied.

MIEBO has a slow rate of evaporation15

Graph outlining evaporation rates of perfluorohexyloctane vs perfluorobutylpentane
Droplet with callout: <1.5% OF MIEBO EVAPORATED in 1 hour vs 93% with an SFA that has a shorter chain length[11]

Semifluorinated alkane (SFA) evaporation rate at physiological temperature in an in vitro gravimetric assay (n = 3; mean ± standard error of the mean).15

The clinical significance of this data has not been established.

Study design: The evaporation rate of MIEBO and perfluorobutylpentane was assessed gravimetrically by placing 500 μL in a preweighed tissue culture dish, which was then incubated at 35 ± 3 °C to mimic body temperature. The percentage of MIEBO and perfluorobutylpentane that evaporated per unit time was obtained by weighing the sample immediately after each addition and 0.5, 1, 2, 4, and 24 hours after incubation. All samples were tested in triplicate.15

MIEBO is the ONLY Rx eye drop for DED that directly targets tear evaporation1

In Vitro Evaporation Flashcard image

See MIEBO evaporation results from in vitro studies

DOWNLOAD BROCHURE
bubble-next

UP NEXT

Clinical Data

arrow-circle-right
 
 
*Required fields.

By submitting your information, you consent to receive communications containing information and educational resources about MIEBO, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

*Required fields.

By submitting your information, you consent to receive communications containing information and educational resources about MIEBO, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Click here for full Prescribing Information for MIEBO.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. MIEBO. Prescribing Information. Bausch & Lomb, Inc. 2. Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12(3):1397-1418. doi:10.1007/s40123-023-00669-1 3. Vittitow J, Kissling R, DeCory H, Borchman D. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98:100704. doi:10.1016/j.curtheres.2023.100704 4. Meinert H, Roy T. Semifluorinated alkanes – a new class of compounds with outstanding properties for use in ophthalmology. Eur J Ophthalmol. 2000;10(3):189-197. doi:10.5301/EJO.2008.1838 5. Agarwal P, Khun D, Krösser S, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. Ocul Surf. 2019;17(2):241-249. doi:10.1016/j.jtos.2019.02.010 6. Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III management and therapy. Am J Ophthalmol. 2025;279:289-386. doi:10.1016/j.ajo.2025.05.039 7. Tauber J, Berdy GJ, Wirta DL, Krösser S, Vittitow JL; GOBI Study Group. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516-524. doi:10.1016/j.ophtha.2022.12.021 8. Sheppard JD, Kurata F, Epitropoulos AT, Krösser S, Vittitow JL; MOJAVE Study Group. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023;252:265-274. doi:10.1016/j.ajo.2023.03.008 9. Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154-161. doi:10.1089/jop.2019.0092 10. Krösser S, Grillenberger R, Eickhoff K, Korward J, Cavet ME, Mah FS. Ocular pharmacokinetics and biodistribution of perfluorohexyloctane after topical administration to rabbits. J Ocul Pharmacol Ther. 2025;41(7):370-377. doi:10.1089/jop.2025.0056 11. Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech. 2023;24(2):66. doi:10.1208/s12249-023-02516-9 12. Sheppard JD, Evans DG, Protzko EE. A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution. Am J Manag Care. 2023;29(suppl 14):S251-S259. doi:10.37765/ajmc.2023.89464 13. Data on file. Bausch & Lomb, Inc. 14. Cavet ME, Vittitow JL, Borchman D. Effect of increasing chain length on inhibition of evaporation by perfluoro compounds in an in vitro gravimetric assay. Exp Eye Res. 2026;264:110824. doi:10.1016/j.exer.2025.110824 15. Agarwal P, Scherer D, Günther B, Rupenthal ID. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm. 2018;538(1-2):119-129. doi:10.1016/j.ijpharm.2018.01.019

Expand Expand Expand Expand

INDICATION AND IMPORTANT
SAFETY INFORMATION

INDICATION

MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Click here for full Prescribing Information for MIEBO.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.